Operations: AsiaInfo Technologies Limited generates revenue primarily from its communications software segment, which amounted to CN￥7.89 billion.

Dividend Yield: 8.7%

AsiaInfo Technologies faces challenges with a net loss of RMB 70-120 million for H1 2024 due to external uncertainties and reduced order volumes. Despite this, its dividend payout ratio of 64.4% and cash payout ratio of 72.1% indicate dividends are covered by earnings and cash flows. The company has paid dividends for four years, showing reliability, but the track record is short. Profit margins have decreased from last year, impacting overall financial stability.

• Click here to discover the nuances of AsiaInfo Technologies with our detailed analytical dividend report.

• Our comprehensive valuation report raises the possibility that AsiaInfo Technologies is priced lower than what may be justified by its financials.

Beijing Tong Ren Tang Chinese Medicine

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Beijing Tong Ren Tang Chinese Medicine Company Limited, with a market cap of HK$7.24 billion, manufactures, retails, and wholesales healthcare products and Chinese medicine to both wholesalers and individuals.

Operations: Beijing Tong Ren Tang Chinese Medicine Company Limited generates revenue from three primary segments: Overseas (HK$482.44 million), Hong Kong (HK$1.17 billion), and Mainland China (HK$228.63 million).

Dividend Yield: 3.8%

Beijing Tong Ren Tang Chinese Medicine's dividend payments have been volatile over the past decade, with a payout ratio of 51.1% and a cash payout ratio of 62.9%, indicating dividends are covered by earnings and cash flows. The company recently affirmed a final dividend of HK$0.33 per share for 2023 and appointed Ernst & Young as its new auditor. Despite trading slightly below fair value, the dividend yield is lower than top-tier Hong Kong payers.

• Take a closer look at Beijing Tong Ren Tang Chinese Medicine's potential here in our dividend report.

• Upon reviewing our latest valuation report, Beijing Tong Ren Tang Chinese Medicine's share price might be too optimistic.

Turning Ideas Into Actions

• Unlock our comprehensive list of 82 Top SEHK Dividend Stocks by clicking here.

• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1368 SEHK:1675 and SEHK:3613.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]